The pathobiology of diabetic complications: a unifying mechanism
Simply apply one patch daily for up to 8 hours and enjoy clean, plant-powered support for your wellness journey
In a large phase 3 obesity trial (ACHIEVE-1), orforglipron at daily doses of 3, 12 and 36 mg caused approximately: Diarrhoea: 1926% of participants (vs 9% on placebo) Nausea: 1318% (vs 2% on placebo) Constipation: 817% (vs 4% on placebo) Vomiting: 514% (vs 1% on placebo) Across multiple studies, 617% of people stopped treatment because of side effects, mostly gut-related symptoms
Individual results vary, but clinical studies have shown: Semaglutide : Patients may lose an average of 10% to 15% of their body weight over a 68-week period
Never adjust the dose without medical supervision
You will need to show up for clinic visits regularly, sometimes for over a year